| Date Filed | Type | Description |
| 10/06/2023 |
4
| Huang Jane (President, CMO) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Exercised 9,375 restricted stock units
@ $0 |
|
| 08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
8-K
| Quarterly results |
| 07/06/2023 |
4
| Huang Jane (President, CMO) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Paid exercise price by delivering 3,242 shares
@ $4.65, valued at
$15.1k
Exercised 9,375 restricted stock units
@ $0 |
|
| 06/01/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 05/26/2023 |
4
| Vaddi Krishna (CEO) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Bought 1,000 shares
@ $5.0114, valued at
$5k
Bought 900 shares
@ $5.31, valued at
$4.8k
|
|
| 05/25/2023 |
4
| Lim Bryant David (Chief Legal Officer, Corp Sec.) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Bought 2,400 shares
@ $5.39, valued at
$12.9k
|
|
| 05/25/2023 |
4
| Chardonnet Laurent (CFO) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Bought 5,000 shares
@ $5.5, valued at
$27.5k
|
|
| 05/25/2023 |
4
| Vaddi Krishna (CEO) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Bought 11,856 shares
@ $5.63, valued at
$66.7k
|
|
| 05/24/2023 |
4
| ORBIMED ADVISORS LLC (10% Owner) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Bought 869,565 shares
@ $5.75, valued at
$5M
|
|
| 05/24/2023 |
4
| Bonita David P (10% Owner) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Bought 869,565 shares
@ $5.75, valued at
$5M
|
|
| 05/24/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 28.6% stake in Prelude Therapeutics Incorporated |
| 05/24/2023 |
SC 13D/A
| BAKER BROS. ADVISORS LP reports a 19.5% stake in Prelude Therapeutics Incorporated |
| 05/24/2023 |
4
| BAKER BROS. ADVISORS LP (10% Owner) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Granted 121,178 options to buy
@ $5.75, valued at
$696.8k
Granted 1,327,044 options to buy
@ $5.75, valued at
$7.6M
Granted 970,220 options to buy
@ $0.0001, valued at
$97
Granted 10,625,036 options to buy
@ $0.0001, valued at
$1.1k
|
|
| 05/19/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/19/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 05/18/2023 |
FWP
| Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses: |
| 05/17/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/08/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/08/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/18/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/15/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 03/15/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 03/15/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/15/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/15/2023 |
8-K
| Quarterly results |
| 03/02/2023 |
4
| Lim Bryant David (Chief Legal Officer, Corp Sec.) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Granted 250,000 options to buy
@ $5.93, valued at
$1.5M
|
|
| 02/22/2023 |
3
| Lim Bryant David (Chief Legal Counsel, Corp Sec.) has filed a Form 3 on Prelude Therapeutics Inc |
| 02/14/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 02/13/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/10/2023 |
SC 13G/A
| FMR LLC reports a 10.2% stake in PRELUDE THERAPEUTICS INC |
|